Preview

Экспериментальная и клиническая гастроэнтерология

Расширенный поиск

ИНФЕКЦИЯ, АССОЦИИРОВАННАЯ С CLOSTRIDIUM DIFFI CILE, КАК ОСЛОЖНЕНИЕ АНТИБИОТИКОТЕРАПИИ. ОБЗОР КЛИНИЧЕСКИХ РЕКОМЕНДАЦИЙ

Полный текст:

Аннотация

Статья содержит обзор современных рекомендаций по ведению больных с инфекцией Clostridium difficilе (Сd-И), одной из актуальных и нерешенных проблем современной медицины, риск развития которой возрастает у больных пожилого возраста, с различными сопутствующими заболеваниями. Данные по распространенности данного заболевания в РФ ограничены. Для выявления случаев Сd-И и проведения эффективной антиклостридиальной терапии необходима доступность диагностических тестов, определяющих наличие токсинов Clostridium difficile. Рациональное применение антибактериальных препаратов, разумное ограничение длительности антибактериальной терапии являются неотъемлемыми условиями для снижения риска развития антибиотик-ассоциированной диареи, в том числе ассоциированной с Clostridium difficile инфекцией.

Об авторах

Т. Е. Морозова
ФГАОУ ВО Первый МГМУ имени И. М. Сеченова Минздрава России
Россия


Т. Б. Андрущишина
ФГАОУ ВО Первый МГМУ имени И. М. Сеченова Минздрава России
Россия


И. Л. Царев
ФГАОУ ВО Первый МГМУ имени И. М. Сеченова Минздрава России
Россия


Список литературы

1. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению Clostridium difficile-ассоциированной болезни Российский журнал гастроэнтерол гепатол колопроктол 2016;26(5) 56-65An Epidemic, Toxin Gene-Variant Strain of Clostridium difficile

2. McDonald L. Clifford et al. An Epidemic, Toxin Gene-Variant Strain of Clostridium difficile N Engl J Med 2005; 353:2433-244

3. Loo VG et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365:1693-703.

4. Shim JK et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet. 1998;351:633-6.

5. Longtin Y et al. Effect of Detecting and Isolating Clostridium difficile Carriers at Hospital Admission on the Incidence of C difficile Infections A Quasi-Experimental Controlled Study JAMA Intern Med. 2016;176(6):796-804

6. Волчкова Е. В., Белоусова Е. А., Макарчук П. А., Русанова Е. В., Великанов Е. В. Частота выявления инфекции Clostridium difficile в больничных условиях // Альманах клинической медицины. 2014. № 33 С. 71-76.

7. McDonald L. Clifford, Maria Owings, and Daniel B. Jernigan. “Clostridium Difficile Infection in Patients Discharged from US Short-Stay Hospitals, 1996-2003.” Emerging Infectious Diseases 12.3 (2006): 409-415

8. Pépin JL et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991-2003: a changing pattern disease severity. CMAJ. 2004;17:466-472.

9. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009. Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality. [Accessed 8 January 2013.]; Statisticalbrief #124.

10. Elixhauser A, Steiner C, Gould C. Readmissions following hospitalizations with Clostridium difficile infections, 2009. Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality. [Accessed 8 January 2013.]; Statistical brief #145.

11. Wilcox MH et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. ClinInfectDis. 2012;55:1056-1063.

12. Davies KA et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect. Dis. 14,1208-1219.

13. Martin JS, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):206-16.

14. Cohen SH. et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Infection Control and Hospital Epidemiology; 2010; 31: 431-455

15. Debast SB, Bauer MP, Kuijper EJ. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20 (Suppl 2):1-26.

16. Sartelli et al. WSES guidelines for management of Clostridium difficile infection in surgical patients World Journal of Emergency Surgery (2015) 10:38

17. Zar FA et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-307

18. Kassam Z et al. Clostridium difficile associated risk of death score (CARDS): a novel severity score to predict mortality among hospitalised patients with C. difficile infection. Aliment Pharmacol Ther. 2016;43:725-33.

19. Sunkesula VCK, Kundrapu S, Muganda C, Sethi AK, Donskey CJ. Does empirical Clostridium difficile infection (CDI) therapy result in false-negative CDI diagnostic test results? Clin Infect Dis. 2013;57:494-500.

20. Rokas K, Johnson J, Beardsley J, Ohl C, Luther V, Williamson J. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. Clin Infect Dis. 2015;61:934-41.

21. Li R et al. Efficacy and safety of metronidazole monotherapy versus vancomycin monotherapy or combination therapy in patients with Clostridium difficile infection: a systematic review and meta-analysis. PLoS ONE. 2015;10: e0137252.

22. Goldenberg S et al. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis. 2016;35:251-9.

23. Biswas JS, Patel A, Otter JA, et al. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin. J Hosp Infect. 2015;90:267-70.

24. Deshpande A, Hurless K, Cadnum JL, et al. Effect of fidaxomicin versus vancomycin on susceptibility to intestinal colonization with vancomycin-resistant enterococci and Klebsiella pneumoniae in mice. Antimicrob Agents Chemother. 2016

25. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015 (9) 835-843

26. Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27-37.


Для цитирования:


Морозова Т.Е., Андрущишина Т.Б., Царев И.Л. ИНФЕКЦИЯ, АССОЦИИРОВАННАЯ С CLOSTRIDIUM DIFFI CILE, КАК ОСЛОЖНЕНИЕ АНТИБИОТИКОТЕРАПИИ. ОБЗОР КЛИНИЧЕСКИХ РЕКОМЕНДАЦИЙ. Экспериментальная и клиническая гастроэнтерология. 2017;(6):112-119.

For citation:


Morozova T.E., Andrushchishina T.B., Tsarev I.L. THE INFECTION ASSOCIATED WITH CLOSTRIDIUM DIFFI CILE AS A COMPLICATION OF ANTIBIOTIC THERAPY. REVIEW OF CLINICAL GUIDELINES. Experimental and Clinical Gastroenterology. 2017;(6):112-119. (In Russ.)

Просмотров: 35


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)